Legend Biotech Stands Out Amid Shifting Biotech Market Dynamics

Yesterday marked a standout moment for biotech investors, as Legend Biotech demonstrated resilience during a widespread market decline. The company generated significant interest after sharing promising preclinical results regarding its in vivo CAR-T therapy for Non-Hodgkin’s lymphoma.

This development comes alongside heightened investor enthusiasm for longevity-focused startups and a new licensing agreement announced by Eli Lilly. The positive sentiment underscores the evolving nature of the biotech sector and the ongoing significance of innovative therapies.

Stay informed with exclusive insights and in-depth coverage straight from STAT.

Source link